Number of Participants Answering "Yes," "no," or Not Applicable (N/A) to the Question of Whether the Indicated Factors Influenced Their Preference for Sunitinib or Pazopanib Treatment as Assessed by the Patient Preference Questionnaire
Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer · Source last updated 2017-04-17
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
End of treatment of both study drugs (maximum of 22 weeks)
What was measured
The PPQ is used to measure participants' preference for pazopanib or sunitinib for renal cell carcinoma management and is used to determine a participant's preference for 1 of the 2 drugs given in the 2 double-blind treatment periods. Participants were asked to select 1 of the following: 1. prefer the drug taken as the first treatment; 2. prefer the drug taken as the second treatment; or 3, no preference. Those participants who indicated a preference were asked to select the factors that had an influence on their treatment preference, as well as the most important reason for their preference.
Analysis population: mITT Population. Responses to some categories of the PPQ may be missing for some participants.
Groups in this outcome
Sunitinib
Participants received 4 overencapsulated capsules of sunitinib (either in Period 1 or Period 2), each containing 12.5 mg of sunitinib, OD orally for 4 weeks, followed by 2 weeks off treatment (matching placebo capsules to maintain blind), followed by 50 mg (4 x 12.5 mg) OD orally for 4 weeks. Study drug was taken orally OD without food at least one hour before or two hours after a meal. The capsules were swallowed whole and not crushed or broken. The time of day the study drug was taken remained relatively constant.
Pazopanib
Participants received 4 overencapsulated tablets of pazopanib (either in Period 1 or Period 2), each containing 200 mg of pazopanib, OD orally for 10 weeks. Study drug was taken orally OD without food at least one hour before or two hours after a meal. The capsules were swallowed whole and not crushed or broken. The time of day the study drug was taken remained relatively constant.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
Sunitinib
25
Pazopanib
80
Reported measurements
Fatigue had less impact on life, Yes
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
12
Not reported
Not reported
Not reported
Not reported
Pazopanib
47
Not reported
Not reported
Not reported
Not reported
Fatigue had less impact on life, No
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
8
Not reported
Not reported
Not reported
Not reported
Pazopanib
26
Not reported
Not reported
Not reported
Not reported
Fatigue had less impact on life, not applicable (N
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
5
Not reported
Not reported
Not reported
Not reported
Pazopanib
6
Not reported
Not reported
Not reported
Not reported
Soreness in hands/feet had less impact, Yes
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
6
Not reported
Not reported
Not reported
Not reported
Pazopanib
30
Not reported
Not reported
Not reported
Not reported
Soreness in hands/feet had less impact, No
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
7
Not reported
Not reported
Not reported
Not reported
Pazopanib
22
Not reported
Not reported
Not reported
Not reported
Soreness in hands/feet had less impact, NA
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
12
Not reported
Not reported
Not reported
Not reported
Pazopanib
28
Not reported
Not reported
Not reported
Not reported
Soreness in mouth/throat had less impact, Yes
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
6
Not reported
Not reported
Not reported
Not reported
Pazopanib
32
Not reported
Not reported
Not reported
Not reported
Soreness in mouth/throat had less impact, No
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
8
Not reported
Not reported
Not reported
Not reported
Pazopanib
25
Not reported
Not reported
Not reported
Not reported
Soreness in mouth/throat had less impact, NA
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
11
Not reported
Not reported
Not reported
Not reported
Pazopanib
23
Not reported
Not reported
Not reported
Not reported
Loss of appetite had less impact, Yes
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
10
Not reported
Not reported
Not reported
Not reported
Pazopanib
28
Not reported
Not reported
Not reported
Not reported
Loss of appetite had less impact, No
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
8
Not reported
Not reported
Not reported
Not reported
Pazopanib
28
Not reported
Not reported
Not reported
Not reported
Loss of appetite had less impact, NA
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
7
Not reported
Not reported
Not reported
Not reported
Pazopanib
22
Not reported
Not reported
Not reported
Not reported
Change in hair color had less impact, Yes
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
5
Not reported
Not reported
Not reported
Not reported
Pazopanib
9
Not reported
Not reported
Not reported
Not reported
Change in hair color had less impact, No
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
11
Not reported
Not reported
Not reported
Not reported
Pazopanib
51
Not reported
Not reported
Not reported
Not reported
Change in hair color had less impact, NA
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
9
Not reported
Not reported
Not reported
Not reported
Pazopanib
20
Not reported
Not reported
Not reported
Not reported
Nausea/vomiting had less impact, Yes
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
11
Not reported
Not reported
Not reported
Not reported
Pazopanib
32
Not reported
Not reported
Not reported
Not reported
Nausea/vomiting had less impact, No
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
7
Not reported
Not reported
Not reported
Not reported
Pazopanib
30
Not reported
Not reported
Not reported
Not reported
Nausea/vomiting had less impact, NA
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
7
Not reported
Not reported
Not reported
Not reported
Pazopanib
17
Not reported
Not reported
Not reported
Not reported
Diarrhea had less impact, Yes
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
16
Not reported
Not reported
Not reported
Not reported
Pazopanib
21
Not reported
Not reported
Not reported
Not reported
Diarrhea had less impact, No
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
5
Not reported
Not reported
Not reported
Not reported
Pazopanib
44
Not reported
Not reported
Not reported
Not reported
Diarrhea had less impact, NA
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
4
Not reported
Not reported
Not reported
Not reported
Pazopanib
15
Not reported
Not reported
Not reported
Not reported
Pain in stomach area had less impact, Yes
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
9
Not reported
Not reported
Not reported
Not reported
Pazopanib
23
Not reported
Not reported
Not reported
Not reported
Pain in stomach area had less impact, No
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
4
Not reported
Not reported
Not reported
Not reported
Pazopanib
30
Not reported
Not reported
Not reported
Not reported
Pain in stomach area had less impact, NA
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
12
Not reported
Not reported
Not reported
Not reported
Pazopanib
27
Not reported
Not reported
Not reported
Not reported
Changes in food tastes had less impact, Yes
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
5
Not reported
Not reported
Not reported
Not reported
Pazopanib
44
Not reported
Not reported
Not reported
Not reported
Changes in food tastes had less impact, No
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
14
Not reported
Not reported
Not reported
Not reported
Pazopanib
23
Not reported
Not reported
Not reported
Not reported
Changes in food tastes had less impact, NA
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
6
Not reported
Not reported
Not reported
Not reported
Pazopanib
12
Not reported
Not reported
Not reported
Not reported
Quality of life better, Yes
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
15
Not reported
Not reported
Not reported
Not reported
Pazopanib
65
Not reported
Not reported
Not reported
Not reported
Quality of life better, No
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
6
Not reported
Not reported
Not reported
Not reported
Pazopanib
12
Not reported
Not reported
Not reported
Not reported
Quality of life better, NA
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
4
Not reported
Not reported
Not reported
Not reported
Pazopanib
2
Not reported
Not reported
Not reported
Not reported
Other, Yes
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
5
Not reported
Not reported
Not reported
Not reported
Pazopanib
14
Not reported
Not reported
Not reported
Not reported
Other, No
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
0
Not reported
Not reported
Not reported
Not reported
Pazopanib
0
Not reported
Not reported
Not reported
Not reported
Other, NA
Values in participants · Interval/dispersion: Not reported
Group
Value
Spread
Lower
Upper
Comment
Sunitinib
20
Not reported
Not reported
Not reported
Not reported
Pazopanib
66
Not reported
Not reported
Not reported
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
value
12
group Id
OG001
value
47
title
Fatigue had less impact on life, Yes
categories
measurements
group Id
OG000
value
8
group Id
OG001
value
26
title
Fatigue had less impact on life, No
categories
measurements
group Id
OG000
value
5
group Id
OG001
value
6
title
Fatigue had less impact on life, not applicable (N
categories
measurements
group Id
OG000
value
6
group Id
OG001
value
30
title
Soreness in hands/feet had less impact, Yes
categories
measurements
group Id
OG000
value
7
group Id
OG001
value
22
title
Soreness in hands/feet had less impact, No
categories
measurements
group Id
OG000
value
12
group Id
OG001
value
28
title
Soreness in hands/feet had less impact, NA
categories
measurements
group Id
OG000
value
6
group Id
OG001
value
32
title
Soreness in mouth/throat had less impact, Yes
categories
measurements
group Id
OG000
value
8
group Id
OG001
value
25
title
Soreness in mouth/throat had less impact, No
categories
measurements
group Id
OG000
value
11
group Id
OG001
value
23
title
Soreness in mouth/throat had less impact, NA
categories
measurements
group Id
OG000
value
10
group Id
OG001
value
28
title
Loss of appetite had less impact, Yes
categories
measurements
group Id
OG000
value
8
group Id
OG001
value
28
title
Loss of appetite had less impact, No
categories
measurements
group Id
OG000
value
7
group Id
OG001
value
22
title
Loss of appetite had less impact, NA
denoms
counts
group Id
OG000
value
25
group Id
OG001
value
80
units
Participants
description
The PPQ is used to measure participants' preference for pazopanib or sunitinib for renal cell carcinoma management and is used to determine a participant's preference for 1 of the 2 drugs given in the 2 double-blind treatment periods. Participants were asked to select 1 of the following: 1. prefer the drug taken as the first treatment; 2. prefer the drug taken as the second treatment; or 3, no preference. Those participants who indicated a preference were asked to select the factors that had an influence on their treatment preference, as well as the most important reason for their preference.
groups
description
Participants received 4 overencapsulated capsules of sunitinib (either in Period 1 or Period 2), each containing 12.5 mg of sunitinib, OD orally for 4 weeks, followed by 2 weeks off treatment (matching placebo capsules to maintain blind), followed by 50 mg (4 x 12.5 mg) OD orally for 4 weeks. Study drug was taken orally OD without food at least one hour before or two hours after a meal. The capsules were swallowed whole and not crushed or broken. The time of day the study drug was taken remained relatively constant.
id
OG000
title
Sunitinib
description
Participants received 4 overencapsulated tablets of pazopanib (either in Period 1 or Period 2), each containing 200 mg of pazopanib, OD orally for 10 weeks. Study drug was taken orally OD without food at least one hour before or two hours after a meal. The capsules were swallowed whole and not crushed or broken. The time of day the study drug was taken remained relatively constant.
id
OG001
title
Pazopanib
param Type
NUMBER
population Description
mITT Population. Responses to some categories of the PPQ may be missing for some participants.
reporting Status
POSTED
time Frame
End of treatment of both study drugs (maximum of 22 weeks)
title
Number of Participants Answering "Yes," "no," or Not Applicable (N/A) to the Question of Whether the Indicated Factors Influenced Their Preference for Sunitinib or Pazopanib Treatment as Assessed by the Patient Preference Questionnaire
Triangle